AssuredPartners Investment Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

AssuredPartners Investment Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.5M	Buy	+3,456	New	+$1.61M	0.16%	143

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AssuredPartners Investment Advisors's VRTX Position: Q1 2026 in Review

AssuredPartners Investment Advisors opened a new position in Vertex Pharmaceuticals (VRTX) in Q1 2026: 3,456 shares worth $1.5M. The stake represents 0.16% of the portfolio and ranks #143 among its holdings.

1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

AssuredPartners Investment Advisors held 3,456 shares of Vertex Pharmaceuticals worth $1.5M as of Q1 2026.
Vertex Pharmaceuticals was a new AssuredPartners Investment Advisors position in Q1 2026.
Vertex Pharmaceuticals made up 0.16% of AssuredPartners Investment Advisors's portfolio in Q1 2026, its #143 holding.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on AssuredPartners Investment Advisors's 13F filing for Q1 2026, filed 13 Apr 2026.